These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 24698003

  • 1. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
    Ghose A, Kundu R, Latif T.
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
    [Abstract] [Full Text] [Related]

  • 2. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [Abstract] [Full Text] [Related]

  • 3. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R.
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [Abstract] [Full Text] [Related]

  • 4. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP.
    Cancer; 2010 Sep 15; 116(18):4283-90. PubMed ID: 20564149
    [Abstract] [Full Text] [Related]

  • 5. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Jul 15; 90(7):809-18. PubMed ID: 21229246
    [Abstract] [Full Text] [Related]

  • 6. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
    Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA.
    Cancer; 2012 Jun 01; 118(11):2944-51. PubMed ID: 22006274
    [Abstract] [Full Text] [Related]

  • 7. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
    Shimada K.
    Brain Nerve; 2011 May 01; 63(5):467-72. PubMed ID: 21515926
    [Abstract] [Full Text] [Related]

  • 8. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
    Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E.
    J Clin Oncol; 2011 Jul 10; 29(20):2766-72. PubMed ID: 21646602
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
    Tolley ER, Lewinter C, Pedersen LM, Nielsen TH.
    Haematologica; 2024 Oct 01; 109(10):3327-3337. PubMed ID: 38497149
    [Abstract] [Full Text] [Related]

  • 10. Central nervous system involvement in diffuse large B-cell lymphoma.
    Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y.
    Eur J Haematol; 2010 Jul 01; 85(1):6-10. PubMed ID: 20236301
    [Abstract] [Full Text] [Related]

  • 11. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis MC, Kotsianidis I, Kalpadakis C, Dimopoulos MA, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP.
    Hematol Oncol; 2013 Mar 01; 31(1):10-7. PubMed ID: 22610484
    [Abstract] [Full Text] [Related]

  • 12. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
    Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF.
    Br J Cancer; 2014 Sep 09; 111(6):1072-9. PubMed ID: 25072255
    [Abstract] [Full Text] [Related]

  • 13. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
    Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, McMillan A, Ardeshna KM, Jack A, Smith P, Mouncey P, Pocock C, Radford JA, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Ann Oncol; 2017 Oct 01; 28(10):2511-2516. PubMed ID: 28961838
    [Abstract] [Full Text] [Related]

  • 14. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
    Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR.
    Br J Haematol; 2019 Oct 01; 187(2):185-194. PubMed ID: 31222719
    [Abstract] [Full Text] [Related]

  • 15. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
    Sancho JM, Ribera JM, Working Group on Diagnosis, Prevention and Treatment of CNS Infiltration in Patients with DLBCL.
    Med Clin (Barc); 2016 Jan 15; 146(2):74-80. PubMed ID: 25817451
    [Abstract] [Full Text] [Related]

  • 16. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.
    Kuitunen H, Kaprio E, Karihtala P, Makkonen V, Kauppila S, Haapasaari KM, Kuusisto M, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O.
    Ann Hematol; 2020 Aug 15; 99(8):1823-1831. PubMed ID: 32577843
    [Abstract] [Full Text] [Related]

  • 17. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R.
    Curr Treat Options Oncol; 2018 Sep 10; 19(11):52. PubMed ID: 30203318
    [Abstract] [Full Text] [Related]

  • 18. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, Klasa R, Slack GW, Tan K, Gascoyne RD, Connors JM, Savage KJ.
    Br J Haematol; 2017 Jan 10; 176(2):210-221. PubMed ID: 27739058
    [Abstract] [Full Text] [Related]

  • 19. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.
    Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B.
    Ann Oncol; 2004 Jan 10; 15(1):129-33. PubMed ID: 14679132
    [Abstract] [Full Text] [Related]

  • 20. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.
    Yoo KH, Lee JY, Lim SH, Ko YH, Kim SJ, Kim WS.
    Acta Haematol; 2015 Jan 10; 133(2):179-82. PubMed ID: 25323539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.